IL15 synergizes with radiotherapy to reprogram the tumor immune contexture through a dendritic cell connection

Pilones, Karsten-A; Charpentier, Maud; García-Martínez, Elena; Demaria, Sandra

RICSMUR Principal
→
02. Servicio Murciano de Salud (SMS)
→
02.06. Área de Salud VI Vega Media
→
02.06.01. Investigación y comunicación científica
→
Ver ítem

dc.contributor.author	Pilones, Karsten-A
dc.contributor.author	Charpentier, Maud
dc.contributor.author	García-Martínez, Elena
dc.contributor.author	Demaria, Sandra
dc.date.accessioned	2025-12-03T11:11:42Z
dc.date.available	2025-12-03T11:11:42Z
dc.date.issued	2020
dc.identifier.citation	Pilones KA, Charpentier M, Garcia-Martinez E, Demaria S. IL15 synergizes with radiotherapy to reprogram the tumor immune contexture through a dendritic cell connection. OncoImmunology. enero de 2020;9(1):1790716.
dc.identifier.issn	2162-402X
dc.identifier.uri	https://sms.carm.es/ricsmur/handle/123456789/22940
dc.description.abstract	IL15 is a key cytokine for the activation and survival of anti-tumor effectors CD8(+) T and NK cells. Recently published preclinical studies demonstrate that the therapeutic activity of IL15 requires conventional dendritic cells type 1 (cDC1). Radiotherapy cooperates with IL15 by enhancing cDC1 tumor infiltration via interferon type 1 activation.
dc.language.iso	eng
dc.publisher	Taylor and Francis Inc.
dc.rights	Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional
dc.rights.uri	https://creativecommons.org/licenses/by-nc-nd/4.0	*
dc.subject.mesh	CD8-Positive T-Lymphocytes
dc.subject.mesh	Dendritic Cells
dc.subject.mesh	Humans
dc.subject.mesh	Interleukin-15
dc.subject.mesh	Killer Cells, Natural
dc.subject.mesh	Neoplasms/radiotherapy
dc.title	IL15 synergizes with radiotherapy to reprogram the tumor immune contexture through a dendritic cell connection
dc.type	info:eu-repo/semantics/article
dc.identifier.pmid	32934886
dc.relation.publisherversion	https://www.tandfonline.com/doi/full/10.1080/2162402X.2020.1790716
dc.identifier.doi	10.1080/2162402X.2020.1790716
dc.journal.title	Oncoimmunology